Ocugen pays $15 million upfront to Bharat Biotech for Covaxin rights in Canada

Ocugen pays $15 million upfront to Bharat Biotech for Covaxin rights in Canada Ocugen in a regulatory filing said it has agreed to pay another USD 10 million to Bharat Biotech within a month from the commercial launch of Covaxin in the North American country.

No comments:

Post a Comment